Figure 4
Time course of lymphocyte subsets (median by treatment group). Percentage change from baseline (day –7) based on absolute count values (cells/mm3) on days 1 and 8 during the first and second treatment cycles for: (A) proliferative CD4 T cells (CD3 + CD4 + Ki67+) and memory CD4 T cells (CD3 + CD4 + CD197–CD45RA–); (B) proliferative CD8 T cells (CD3 + CD8 + Ki67+) and memory CD8 T cells (CD3 + CD8 + CD197–CD45RA–); and (C) immature NK cells (CD16–CD56brightCD3–) and mature NK cells CD16 + CD56 + CD3–. (D) sIL-2Ralpha serum concentrations (pg/mL) at baseline and on days 1 and 8 during the first cycle. Graphs show the individual values from 12 NSCLC patients treated with NHS-IL2 at doses of 0.15 mg/kg, 0.30 mg/kg, and 0.45 mg/kg. Bars represent geometric mean values. NK, natural killer; NSCLC, non-small cell lung cancer; sIL-2Ralpha, soluble IL-2 receptor alpha.